BioCentury
ARTICLE | Clinical News

Peregrine preclinical data

January 16, 2006 8:00 AM UTC

In a mouse model of pancreatic cancer, Tarvacin with gemcitabine combination reduced tumor burden 3- to 5-fold, compared to a 1.5- to 2-fold reduction with Tarvacin and gemcitabine alone, respectively...